Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: MSI-High Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT07213609
View directory record Official record
Conditions
Neoplasms, Colorectal, Neoplasms
Interventions
GSK5460025
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Detroit, Michigan • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284
View directory record Official record
Conditions
Neoplasms
Interventions
Dostarlimab
Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
48
States / cities
Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173
View directory record Official record
Conditions
Advanced Malignancies
Interventions
INCAGN01949, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

NCT02060188
View directory record Official record
Conditions
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
Interventions
Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

NCT04116320
View directory record Official record
Conditions
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
Interventions
Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
Device · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

NCT06034860
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions
MT-8421, Nivolumab
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 19, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

NCT05909995
View directory record Official record
Conditions
Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Interventions
INCB 99280 with Ipilimumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

NCT03104439
View directory record Official record
Conditions
Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
Interventions
Nivolumab, Ipilimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Withdrawn Phase 2 Interventional

Anti-PD-1 +/- RT for MSI-H Solid Tumors

NCT04001101
View directory record Official record
Conditions
Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
RT and Anti-PD-1, Anti-PD-1
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334
View directory record Official record
Conditions
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Interventions
LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Early Phase 1 Interventional

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

NCT03832569
View directory record Official record
Conditions
Solid Tumors, Identified by NGS, PCR or IHC
Interventions
Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

NCT05239546
View directory record Official record
Conditions
Colon Cancer, dMMR Colorectal Cancer
Interventions
Dostarlimab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Orange City, Florida • Athens, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042
View directory record Official record
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 19, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

NCT02952989
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
SGN-2FF, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

NCT04774419
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Intensity modulated radiation therapy (IMRT), Dostarlimab, Hypofractionated IMRT
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

NCT04098068
View directory record Official record
Conditions
High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable)
Interventions
MK-3475
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 19, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005, pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Morristown, New Jersey • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 19, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 19, 2026, 4:53 AM EDT